List of Stendra drug patents
Stendra is owned by Metuchen Pharms.
Stendra contains Avanafil.
Stendra has a total of 2 drug patents out of which 0 drug patents have expired.
Stendra was authorised for market use on 27 April, 2012.
Stendra is available in tablet;oral dosage forms.
Stendra can be used as treatment of erectile dysfunction.
The generics of Stendra are possible to be released after 18 October, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6656935 | METUCHEN PHARMS | Aromatic nitrogen-containing 6-membered cyclic compounds |
Apr, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7501409 | METUCHEN PHARMS | Preparations for oral administration |
May, 2023
(a month from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Oct 18, 2025 |
Drugs and Companies using AVANAFIL ingredient
Market Authorisation Date: 27 April, 2012
Treatment: Treatment of erectile dysfunction
Dosage: TABLET;ORAL
STENDRA family patents
9
Japan
6
United States
5
Australia
5
China
3
Korea, Republic of
3
Canada
3
European Union
2
Austria
2
Mexico
2
Hong Kong
2
Hungary
2
Norway
2
Spain
2
New Zealand
1
Israel
1
South Africa
1
Denmark
1
Turkey
1
Belgium
1
Russia
1
Germany
1
Argentina
1
Brazil
1
Portugal
1
Malaysia
1
Taiwan, Province of China
1
Luxembourg
1
Bulgaria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic